- Home
- LU vs BHVN Comparison
LU vs BHVN Comparison
Compare LU & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LU
- BHVN
- Stock Information
- Founded
- LU 2005
- BHVN 2013
- Country
- LU China
- BHVN United States
- Employees
- LU N/A
- BHVN N/A
- Industry
- LU Finance: Consumer Services
- BHVN Biotechnology: Pharmaceutical Preparations
- Sector
- LU Finance
- BHVN Health Care
- Exchange
- LU Nasdaq
- BHVN Nasdaq
- Market Cap
- LU 2.1B
- BHVN 1.9B
- IPO Year
- LU 2020
- BHVN 2017
- Fundamental
- Price
- LU $2.36
- BHVN $20.37
- Analyst Decision
- LU Hold
- BHVN Strong Buy
- Analyst Count
- LU 2
- BHVN 14
- Target Price
- LU $2.98
- BHVN $63.15
- AVG Volume (30 Days)
- LU 4.4M
- BHVN 1.7M
- Earning Date
- LU 04-29-2025
- BHVN 05-08-2025
- Dividend Yield
- LU 10.04%
- BHVN N/A
- EPS Growth
- LU N/A
- BHVN N/A
- EPS
- LU N/A
- BHVN N/A
- Revenue
- LU $4,671,260,668.00
- BHVN N/A
- Revenue This Year
- LU N/A
- BHVN N/A
- Revenue Next Year
- LU $1.48
- BHVN $65.26
- P/E Ratio
- LU N/A
- BHVN N/A
- Revenue Growth
- LU N/A
- BHVN N/A
- 52 Week Low
- LU $2.00
- BHVN $15.79
- 52 Week High
- LU $4.94
- BHVN $55.70
- Technical
- Relative Strength Index (RSI)
- LU 32.21
- BHVN 39.78
- Support Level
- LU $2.32
- BHVN $15.79
- Resistance Level
- LU $2.70
- BHVN $19.30
- Average True Range (ATR)
- LU 0.17
- BHVN 2.20
- MACD
- LU -0.04
- BHVN 0.26
- Stochastic Oscillator
- LU 8.11
- BHVN 42.84
About LU Lufax Holding Ltd each representing two (2)
Lufax Holding Ltd is a technology-empowered personal financial services platform in China. The company address the large unmet demand for personal lending among small business owners as well as salaried workers in China and provides tailor-made wealth management solutions to China's middle class and affluent population. Its platform has two hubs namely Retail Credit Facilitation Hub and Wealth Management Hub.
About BHVN Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.